Navigation Links
VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis
Date:5/23/2011

evelop an efficacious BV product that avoids the side-effects and other shortcomings of conventional antibiotics."

"This Phase 2 study was a crucial test of the product and these exciting results confirm the significant commercial potential of VivaGel(R) for BV. As well as the great outcome for the acute treatment opportunity, we are also very encouraged by the implication of these results for the additional application of VivaGel(R) for prevention of BV recurrence."

"It is particularly pleasing to see such high rates of resolution of symptoms and excellent patient acceptability", she said.

Existing treatments for BV, such as the conventional antibiotics metronidazole and clindamycin, have published Clinical Cure rates of between 35% and 65% when assessed 2-3 weeks after completion of therapy. Unfortunately, existing products have significant shortcomings in terms of side-effects or tolerability, high levels of antibiotic resistance and in some cases incompatibility with condoms.

In contrast, whist having comparable efficacy, VivaGel(R) is well tolerated, is not absorbed (and so is free from systemic effects), can be used with condoms, and has the real potential to be used for prolonged periods to prevent recurrence of BV.

Clinical Cure 2 to 3 weeks after completion of treatment is currently the US FDA's preferred endpoint for assessing cure of BV.  In addition to cure of BV achieved with VivaGel(R) at that time, acceptability of the product was very high with 83% of patients using 1% VivaGel(R) extremely satisfied, very satisfied or satisfied with the product when taking all aspects of the treatment into account, compared with just 35% of patients using the placebo.

Professor George Kinghorn, of the Department of Genitourinary Medicine at the Royal Hallamshire Hospital, Sheffield, UK, a leading expert in BV and Medical Advisor to Starpharma on this Phase 2 study, commented: "These significant efficacy results are very
'/>"/>

SOURCE Starpharma
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
10. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
11. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... , May 17, 2013 ... and Switzerland,s Cytos Biotechnology AG today ... a Phase 1 clinical trial with their H1N1 influenza vaccine ... technology. In this first Phase 1 clinical trial, the safety ... to protect against H1N1 influenza infection will be evaluated. ...
(Date:5/16/2013)... N.J. , May 16, 2013  PTC Therapeutics, ... statement on Form S-1 with the U.S. Securities and ... offering of its common stock. The number of shares ... offering have not been determined. (Logo:  ... Suisse are acting as joint book-running managers for the ...
(Date:5/16/2013)... , May 16, 2013  Today, the National Patient ... House of Representatives recently approved a bill ... from charging patients higher out-of-pocket fees for newer, more ... of which have more severe side-effects. However, the bill ... $300, which will continue to be a barrier to ...
Breaking Medicine Technology:A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3
... Feb. 1, 2011 West Pharmaceutical Services, Inc. (NYSE: ... UBS 21st Annual Global Healthcare Services Conference in New York, ... outlook on Tuesday, February 8, 2011 at 1:00 PM ET. ... as well as a copy of the presentation materials, will ...
... 1, 2011 Cardinal Health today announced that its board of ... payable on April 15 to shareholders of record on April 1. ... About Cardinal Health Headquartered ... is a $99 billion health care services company that ...
Cached Medicine Technology:Cardinal Health Declares Regular Quarterly Dividend 2
(Date:5/18/2013)... CA (PRWEB) May 18, 2013 The topics ... classes are scrum framework, scrum roles, scrum meetings, scrum artifacts, ... units (8 PDUs) for attending them. , These trainings are ... It is also ideal for those who will be a ... or those who want to explore Agile and Scrum, but ...
(Date:5/18/2013)... According to the the Stevens Johnson Syndrome Foundation, ... is a severe allergic reaction usually to medicine (i). ... can quickly advance causing blistering and large areas of dead ... SJS can develop at any time and seriously affect both ... Manute Bol, passed away after he received kidney medicine which ...
(Date:5/17/2013)... YORK, May 18, 2013. Chronic trauma can inflict lasting ... Previous imaging studies of people with post-traumatic stress disorder, ... over-or under-react in response to stressful tasks, such as ... of a threatening face. Now, researchers at NYU School ... happens in the brains of combat veterans with PTSD ...
(Date:5/17/2013)... Stryker hip lawsuit claims filed ... ABG II Modular-Neck Hip Stem recall continue to move forward ... According to court documents, a Case Management Conference was held ... which time the Court, among other things, set deadlines by ... submit Fact Sheets to Defendant and Liaison Counsel. The ...
(Date:5/17/2013)... Martinson-Nicholls new slip-resistant stair treads ... renovation tread used on steps that require an ... renovation projects, our treads and nosings deliver maximum ... compliment building designs. Bold Step is strong enough ... stairs such as basement or deck steps. , ...
Breaking Medicine News(10 mins):Health News:Affordable Scrum Trainings In Irvine by Conscires Agile Practices 2Health News:Affordable Scrum Trainings In Irvine by Conscires Agile Practices 3Health News:Injury Law Firm Announces New Informative Graphic on Common Medicines That Have Allegedly Been Linked to Stevens Johnson Syndrome 2Health News:For combat veterans suffering from post-traumatic stress disorder, 'fear circuitry' in the brain never rests 2Health News:Stryker Hip Lawsuit News: Bernstein Liebhard LLP Reports on Recent Case Management Conference in New Jersey Stryker Hip Recall Litigation 2Health News:Stryker Hip Lawsuit News: Bernstein Liebhard LLP Reports on Recent Case Management Conference in New Jersey Stryker Hip Recall Litigation 3Health News:New Bold Step Renovation Stair Treads and Nosings from Martinson-Nicholls Add Slip Resistance to Stairs 2
... , , CHICAGO, July 21 ... new PLEX-ID system currently in development for detecting and characterizing ... in hospitals and other clinical sites. PLEX-ID is the next ... an innovative portfolio of instruments and tests the company is ...
... NORTH HOLLYWOOD, Calif., July 21 /PRNewswire-FirstCall/ -- IPC The Hospitalist ... group practice company, announced today that it will report results for the ... 6, 2009, after the market close. , , ... p.m. ET (2:00 p.m. PT) on August 6, 2009 and will be ...
... survey finds, , TUESDAY, July 21 (HealthDay News) -- Most ... individual health insurance policy on their own never end up ... according to a new study. , A report by the ... health policy reform, found that roughly three of every four ...
... , MINNEAPOLIS, July 21 Norwell VNA ... it has entered into a business relationship with Cardiocom ((R)) ... to patients with chronic illness. Cardiocom, the Experts in ... provider of award-winning telehealth solutions. , , ...
... - (Ocean Nutrition Canada) - These days, consumers ... dollars, buying products that are local, recycled, or ... is literally changing the world: If given the ... from certified sustainable sources, research from the US-based ...
... SAN DIEGO, July 21 The Department of ... the enterprise authentication tool for remote access to VA ... provide more veteran-centric benefit and healthcare services online. ... solution delivered through multiple channels without the cost and ...
Cached Medicine News:Health News:Abbott Introduces Molecular Diagnostic System Intended for Broad Identification of Infectious Agents 2Health News:IPC The Hospitalist Company, Inc. to Report Second Quarter 2009 Results 2Health News:Millions in U.S. Can't Afford Health Insurance 2Health News:Norwell VNA and Hospice Selects Cardiocom Telehealth as Its New Technology Vendor 2Health News:Association of Peruvian Anchovy Producers Pursues MSC Certification 2Health News:Association of Peruvian Anchovy Producers Pursues MSC Certification 3Health News:Association of Peruvian Anchovy Producers Pursues MSC Certification 4Health News:Association of Peruvian Anchovy Producers Pursues MSC Certification 5Health News:Association of Peruvian Anchovy Producers Pursues MSC Certification 6Health News:Department of Veterans Affairs Selects Anakam to Provide Trusted Authentication as Part of Its Overall Identity Management Strategy 2Health News:Department of Veterans Affairs Selects Anakam to Provide Trusted Authentication as Part of Its Overall Identity Management Strategy 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: